Peer Review reports
From: Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer
| Original Submission | ||
|---|---|---|
| 26 Jan 2021 | Submitted | Original manuscript |
| 9 Dec 2020 | Reviewed | Reviewer Report |
| 15 Feb 2021 | Author responded | Author comments - Becky AS Bibby |
| Resubmission - Version 2 | ||
| 15 Feb 2021 | Submitted | Manuscript version 2 |
| 29 Mar 2021 | Reviewed | Reviewer Report |
| 31 Mar 2021 | Reviewed | Reviewer Report |
| 4 May 2021 | Author responded | Author comments - Becky AS Bibby |
| Resubmission - Version 3 | ||
| 4 May 2021 | Submitted | Manuscript version 3 |
| 12 May 2021 | Reviewed | Reviewer Report |
| 14 May 2021 | Reviewed | Reviewer Report |
| 26 May 2021 | Author responded | Author comments - Becky AS Bibby |
| Resubmission - Version 4 | ||
| 26 May 2021 | Submitted | Manuscript version 4 |
| Publishing | ||
| 4 Jun 2021 | Editorially accepted | |
| 1 Jul 2021 | Article published | 10.1186/s12894-021-00856-x |
You can find further information about peer review here.